Aspire BioPharma, Inc. (ASBP) — Cash Flow Quality Index

Latest as of June 2023: -0.10x

Aspire BioPharma, Inc. (ASBP) has a Cash Flow Quality Index of -0.10x as of June 2023. Operating cash flow of $-189.95K is below net income of $1.81 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore Aspire BioPharma, Inc. (ASBP) cash conversion ratio to assess how effectively this company generates cash.

Cash Flow Quality Index

-0.10x
Operating CF / Net Income

Operating Cash Flow

$-189.95K
USD

Net Income

$1.81 Million
USD

Data as of

Jun 2023
Most recent filing

Aspire BioPharma, Inc. Cash Flow Quality Index (2022–2023)

Historical Cash Flow Quality Index for Aspire BioPharma, Inc. across 2 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check Aspire BioPharma, Inc. total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.

Annual Cash Flow Quality Index for Aspire BioPharma, Inc. (2022–2023)

Year-by-year earnings quality comparison for Aspire BioPharma, Inc.. For live market cap and the full company financial profile, see ASBP company net worth.

Year Quality Index Operating CF (USD) Net Income YoY Change
2023 -0.15x $-653.11K $4.46 Million ▲ +65.3%
2022 -0.42x $-1.41 Million $3.34 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.